Log In
BCIQ
Print this Print this
 

KAHR-101

  Manage Alerts
Collapse Summary General Information
Company Kahr Medical Ltd.
DescriptionFusion protein that links portions of Fn14 and TRAIL immune-related membrane proteins
Molecular Target TNF-like weak inducer of apoptosis receptor (TWEAKR) (TNFRSF12A) (FN14) ; Tumor necrosis factor (TNF) receptor superfamily member 10a (TNFRSF10A) (DR4) (TRAILR1) (CD261)
Mechanism of Action 
Therapeutic ModalityBiologic: Fusion protein

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$3.0M

$3.0M

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

04/17/2011

$3.0M

$3.0M

0

Get a free BioCentury trial today